Voltaren is owned by Haleon (the United Kingdom, LSE: HLN), which was separated from GSK on 18 July 2022.[1][2] Before Haleon, Voltaren was owned by GSK from 2015 to 2022.[2]
Voltaren is a diclofenac anti-inflammatory sold over the counter as a topical gel for joint and muscle pain. It came to the business through the Novartis consumer health joint venture and is sold as Voltarol in the United Kingdom.
What Haleon's annual report says about Voltaren
Sentences about Voltaren from Haleon's latest annual filing[1], copied word for word.
Market drivers Socioeconomic and geopolitical dynamics shifting Consumer needs evolving Channel landscape evolving Regulatory dynamics changing 10 Haleon Annual Report and Form 20-F 2025 Activity examples Key growth driver and 2025 activities Market driver(s) Geographic expansion Expanded Voltaren 2% into China.
Voltaren became the official licensed pain killer of the UEFA Champions League, a first for Haleon, Voltaren and UEFA.
The campaign, designed to strengthen Voltaren's relevance among younger, active consumers, culminated at the final in Munich in May 2025 and was activated across broad media channels, including in-store displays and an experiential zone within the stadium.
How often Haleon names Voltaren in its annual report
A plain count of the times the name appears in the text of each annual report, not counting the start of a sentence. A brand that an owner writes about more is usually one it treats as central. The brand is named less often than it was three years earlier.
Haleon is a publicly listed company headquartered in Weybridge, United Kingdom, founded in 2022. Brandtree records 8 brands under its control, and it is listed as LSE: HLN and NYSE: HLN.
Haleon is the consumer health business demerged from GSK in July 2022, having earlier absorbed Pfizer's consumer health portfolio through a joint venture. It is the largest standalone consumer health company in the world, built on oral health, pain relief, respiratory health and vitamins.
Brandtree records a controlling owner for 128 brands that began in Switzerland.
35 of them (27%) are now controlled by a company headquartered in another country, Voltaren among them.
GSK demerged its consumer healthcare business as Haleon, listing it in London and New York in July 2022. The business already contained Pfizer's consumer health portfolio, contributed to a joint venture in 2019, which is how Advil and Centrum came to sit alongside Sensodyne and Panadol.
The parent company of Voltaren is Haleon, a publicly listed company headquartered in the United Kingdom.
Is Voltaren Swiss or British?
⌄
Voltaren originated in Switzerland in 1974, but it is owned today by Haleon, which is headquartered in the United Kingdom. So Voltaren is a Swiss-origin brand under British ownership.
Since when has Haleon owned Voltaren?
⌄
Haleon has owned Voltaren since 18 July 2022.
Who owned Voltaren before Haleon?
⌄
Before Haleon, Voltaren was owned by GSK from 2015 until 2022.
Is Voltaren still owned by Haleon?
⌄
Yes. As of 9 October 2026, Voltaren is still owned by Haleon. The ownership record was last checked against primary sources on that date.
Sources (2) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
Brandtree needs to remember this choice and does not set any other cookie unless you accept.
If you choose “Accept all”, we also use Google Analytics cookies to count visits and see which pages help, so we can improve the site.
If you choose “Accept required”, no analytics cookie is set. Google Analytics still receives a cookieless ping with the page address and your IP address. No advertising is used either way. Privacy policy